• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    4/30/25 4:10:13 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    8-K
    false000113872300011387232025-04-302025-04-30

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 30, 2025

     

     

    ACCURAY INCORPORATED

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33301

    20-8370041

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1240 Deming Way

     

    Madison, Wisconsin

     

    53717-1954

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 608 824-2800

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    ARAY

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On April 30, 2025, the Company issued a press release announcing its financial results for the third quarter ended March 31, 2025. A copy of the Company’s press release dated April 30, 2025, titled “Accuray Reports Fiscal 2025 Third Quarter Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.

     

    Item 7.01 Regulation FD Disclosure.

    Spokespersons of the Company plan to present the information in the presentation attached hereto as Exhibit 99.2 to analysts and investors from time to time on or after April 30, 2025. The presentation will be available on the Company’s Investor Relations website at: http://investors.accuray.com.

    The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report. For important information about forward looking statements, see the slide titled “Forward-Looking Statements” in Exhibit 99.2 attached hereto.

    The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.

    The information contained in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press release dated April 30, 2025, titled “Accuray Reports Fiscal 2025 Third Quarter Financial Results”

    99.2

    Accuray Third Quarter Fiscal 2025 Earnings Call Presentation

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    ACCURAY INCORPORATED

     

     

     

     

    Date:

    April 30, 2025

    By:

    /s/ Ali Pervaiz

     

     

     

    Ali Pervaiz
    Senior Vice President & Chief Financial Officer

     

    3


    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

      MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares"). As part of the exchange consideration, Accuray will pay exchanging holders an aggregate of approximately $68.6 million in cash. The Exchange is expected to close on or about June 11, 202

      6/6/25 7:30:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Participate in the Jefferies Global Healthcare Conference 2025

      MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o

      5/29/25 7:30:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Accuray Incorporated

      SCHEDULE 13D - ACCURAY INC (0001138723) (Subject)

      6/17/25 1:25:59 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      6/6/25 7:36:36 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Accuray Incorporated

      SD - ACCURAY INC (0001138723) (Filer)

      5/30/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Whitters Joseph E bought $62,335 worth of shares (50,000 units at $1.25), increasing direct ownership by 9% to 611,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      6/16/25 4:10:10 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care